Acquisition Completed
XenoTherapeutics acquisition of Repare Therapeutics
US$2.20 cash per share
Advisers
Repare Therapeutics
Target
XenoTherapeutics
Acquirer
Not disclosed
- Target
- Repare Therapeutics
- Acquirer
- XenoTherapeutics
- Target based in
- Canada
- Buyer based in
- United States (unverified)
- Completed
- 28 Jan 2026
- Sector
- Biotech
- Tags
- Biotech, Oncology
In the league tables
Similar deals
- GSK acquisition of trispecific T cell-engager (TCE) asset Sep 2026 · US$750m · Biotech
- Novartis acquisition of Myricx Bio Jul 2026 · US$1.1bn · Biotech
- Ipsen acquisition of Kartos Therapeutics Jun 2026 · US$450m · Biotech
- Passage Bio and Remix Therapeutics merger Jun 2026 · Biotech
- GSK acquisition of Nuvalent Jun 2026 · US$11bn · Biotech
Sources
- 28 Jan 2026 Repare Announces Completion of Acquisition by XenoTherapeutics cooley.com